| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
1-Bromo-3,5-dimethoxybenzene does not have a defined pharmacological target of its own as it is a synthetic intermediate rather than a drug substance. However, it is widely used as a building block for the synthesis of various biologically active compounds. Through palladium-catalyzed cross-coupling reactions, this bromide can be converted to a wide range of arylated products with potential activity against various biological targets including kinases, GPCRs, and enzymes. The dimethoxyphenyl motif is found in numerous natural products and pharmaceutical compounds with diverse activities including anticancer, anti-inflammatory, and antimicrobial properties.
|
|---|---|
| ln Vitro |
Through cross-coupling processes, 1-bromo-3,5-dimethoxybenzene is employed as an intermediary in the manufacture of pharmacological inhibitors.
In vitro, 1-Bromo-3,5-dimethoxybenzene is primarily used as a chemical reagent and synthetic intermediate rather than being evaluated for direct biological activity. It is employed in the synthesis of various pharmaceutical compounds that are subsequently tested in in vitro assays. The compound is soluble in common organic solvents such as DMSO, DMF, dichloromethane, and THF, making it suitable for use in solution-phase organic synthesis and medicinal chemistry workflows. As a brominated arene, it is a common building block for the construction of drug-like molecules in high-throughput screening libraries via cross-coupling chemistry. |
| ln Vivo |
In vivo activity data for 1-Bromo-3,5-dimethoxybenzene itself are not available, as the compound is not intended for direct in vivo administration. Rather, it is a precursor used in the synthesis of drug candidates that are subsequently evaluated in animal models. The compound's in vivo relevance is therefore indirect, through the biological activities of the final pharmaceutical compounds derived from it.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding studies, 1-Bromo-3,5-dimethoxybenzene is not typically evaluated as a test compound itself. Instead, it serves as a reagent for the synthesis of test compounds. The compound's properties include a molecular weight of approximately 217 g/mol and moderate lipophilicity (estimated logP ~2.5-3.0) due to the two methoxy groups and the bromine substituent. The bromine atom serves as a versatile handle for cross-coupling reactions to introduce various substituents for structure-activity relationship studies.
|
| Cell Assay |
For in vitro cell-based experiments, 1-Bromo-3,5-dimethoxybenzene is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations in appropriate cell culture medium. The dimethoxyphenyl moiety may contribute to the overall lipophilicity and cell permeability of the final drug candidates.
|
| Animal Protocol |
In vivo animal studies using 1-Bromo-3,5-dimethoxybenzene are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For pharmaceutical candidates derived from this building block, efficacy studies would typically be performed in mouse models of the relevant disease (e.g., tumor xenografts for anticancer agents, inflammation models for anti-inflammatory agents). Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with appropriate pharmacokinetic and pharmacodynamic endpoints. Specific protocols for the intermediate compound are not documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 1-Bromo-3,5-dimethoxybenzene as a standalone compound are not characterized in the literature, as it is a synthetic intermediate rather than a drug candidate. The compound has a molecular weight of approximately 217 g/mol, which is within the favorable range for oral bioavailability. The two methoxy groups may be subject to metabolic O-demethylation by cytochrome P450 enzymes, which could affect the pharmacokinetic profile of the parent compound. However, empirical pharmacokinetic data are not available for this intermediate compound.
|
| Toxicity/Toxicokinetics |
1-Bromo-3,5-dimethoxybenzene is a research chemical and should be handled with appropriate laboratory safety precautions. As a brominated aromatic compound, it may pose risks of skin and eye irritation. The compound may be harmful if swallowed, inhaled, or absorbed through skin. Specific LD₅₀ values and acute toxicity classifications are not available in the public literature. Standard safety practices include the use of personal protective equipment (gloves, safety goggles, lab coat), working in a fume hood, and avoiding inhalation and skin contact. The compound is intended for research use only.
|
| Additional Infomation |
1-Bromo-3,5-dimethoxybenzene (3,5-Dimethoxybromobenzene) (CAS 20469-65-2) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are in organic synthesis as a building block for the construction of complex molecules through cross-coupling reactions. The dimethoxy-substituted phenyl ring is a common motif in natural products and pharmaceuticals. The bromine atom provides a versatile handle for introducing diverse substituents via palladium-catalyzed coupling reactions. The compound is used in medicinal chemistry for the synthesis of drug candidates and in academic research for the preparation of novel compounds. No clinical trials or approved indications exist for this compound. It is intended for laboratory research use only.
|
| Molecular Formula |
C8H9BRO2
|
|---|---|
| Molecular Weight |
217.06
|
| Exact Mass |
215.978
|
| CAS # |
20469-65-2
|
| PubChem CID |
639187
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
246.0±20.0 °C at 760 mmHg
|
| Melting Point |
62-66ºC
|
| Flash Point |
103.1±17.3 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.528
|
| LogP |
2.94
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
107
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(=CC(=C1)Br)OC
|
| InChi Key |
KRWRFIMBWRVMKE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H9BrO2/c1-10-7-3-6(9)4-8(5-7)11-2/h3-5H,1-2H3
|
| Chemical Name |
1-bromo-3,5-dimethoxybenzene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~460.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (23.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (23.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 5 mg/mL (23.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6070 mL | 23.0351 mL | 46.0702 mL | |
| 5 mM | 0.9214 mL | 4.6070 mL | 9.2140 mL | |
| 10 mM | 0.4607 mL | 2.3035 mL | 4.6070 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
